Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Bone Biologics (BBLGW) EBITDA Margin (2016 - 2017)

Bone Biologics (BBLGW) has disclosed EBITDA Margin for 2 consecutive years, with 89.83% as the latest value for Q4 2017.

  • Quarterly EBITDA Margin changed N/A to 89.83% in Q4 2017 from the year-ago period, while the trailing twelve-month figure was 59.38% through Dec 2017, down 191825.0% year-over-year, with the annual reading at 2568.41% for FY2025, 138430.0% up from the prior year.
  • EBITDA Margin for Q4 2017 was 89.83% at Bone Biologics, down from 90.83% in the prior quarter.
  • The five-year high for EBITDA Margin was 2936.14% in Q1 2016, with the low at 206.36% in Q2 2017.